Global Precision Medicine Partnering Terms and Agreements 2014-2020

$3,495.00

The Global Precision Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the precision medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2020
Number of pages
650+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2108

The Global Precision Medicine Partnering terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the Precision medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

This report provides details of the latest Precision Medicine agreements announced in the life sciences since 2014.

 

The report takes the reader through a comprehensive review Precision Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Precision Medicine partnering deals.

 

The report presents financial deal term values for Precision Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Precision Medicine partnering field; both the leading deal values and most active Precision Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 1000 online deal records of actual Precision Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Precision Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Precision Medicine dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Precision Medicine deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Precision Medicine dealmaking with a brief summary followed by a comprehensive listing of Precision Medicine deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Precision Medicine partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Precision Medicine partnering deals signed and announced since Jan 2014. The chapter is organized by specific Precision Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Precision Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Precision Medicine partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Precision Medicine technologies and products.

 

Key benefits

 

Global Precision Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Precision Medicine deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Precision Medicine agreements with numerous real life case studies
  • Detailed access to actual Precision Medicine contracts entered into by leading biopharma companies
  • Identify most active Precision Medicine dealmakers since 2014
  • Insight into terms included in a Precision Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Precision Medicine Partnering Terms and Agreements 2014-2020 is intended to provide the reader with an in-depth understanding and access to Precision Medicine trends and structure of deals entered into by leading companies worldwide.

 

Precision Medicine Partnering Terms and Agreements includes:

 

  • Trends in Precision Medicine dealmaking in the biopharma industry since 2014
  • Analysis of Precision Medicine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Precision Medicine deals
  • Access to Precision Medicine contract documents
  • Leading Precision Medicine deals by value since 2014
  • Most active Precision Medicine dealmakers since 2014

 

In Global Precision Medicine Partnering Terms and Agreements 2014-2020, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Precision Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 1000 Precision Medicine deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Precision Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Precision Medicine deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Precision Medicine agreements with numerous real life case studies
  • Detailed access to actual Precision Medicine contracts entered into by leading biopharma companies
  • Identify most active Precision Medicine dealmakers since 2014
  • Insight into terms included in a Precision Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Precision Medicine dealmaking

 

2.1. Introduction

2.2. Precision Medicine partnering over the years

2.3. Most active Precision Medicine dealmakers

2.4. Precision Medicine partnering by deal type

2.5. Precision Medicine partnering by therapy area

2.6. Deal terms for Precision Medicine partnering

2.6.1 Precision Medicine partnering headline values

2.6.2 Precision Medicine deal upfront payments

2.6.3 Precision Medicine deal milestone payments

2.6.4 Precision Medicine royalty rates

 

Chapter 3 – Leading Precision Medicine deals

 

3.1. Introduction

3.2. Top Precision Medicine deals by value

 

Chapter 4 – Most active Precision Medicine dealmakers

 

4.1. Introduction

4.2. Most active Precision Medicine dealmakers

4.3. Most active Precision Medicine partnering company profiles

 

Chapter 5 – Precision Medicine contracts dealmaking directory

 

5.1. Introduction

5.2. Precision Medicine contracts dealmaking directory

 

Chapter 6 – Precision Medicine dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Precision Medicine deals by company A-Z

 

Appendix 2 – Precision Medicine deals by stage of development

 

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation

 

Appendix 3 – Precision Medicine deals by deal type

 

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation        

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

 

Appendix 4 – Precision Medicine deals by therapy area

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures


Figure 1: Precision Medicine partnering since 2014

Figure 2: Active Precision Medicine dealmaking activity since 2014

Figure 3: Precision Medicine partnering by deal type since 2014

Figure 4: Precision Medicine partnering by disease type since 2014

Figure 5: Precision Medicine deals with a headline value

Figure 6: Precision Medicine deals with an upfront value

Figure 7: Precision Medicine deals with a milestone value

Figure 8: Precision Medicine deals with a royalty rate value

Figure 9: Top Precision Medicine deals by value since 2014

Figure 10: Most active Precision Medicine dealmakers since 2014

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1CellBiO, 2bPrecise, 2X Oncology, 3D Systems, 4D Pharma, 20/20 GeneSystems, 23andMe, 48Hour Discovery, A*STAR Agency for Science, Technology and Research, A*STAR Bioinformatics Institute, A*STAR Bioprocessing Technology Institute, A*STAR Genome Institute of Singapore, Abbott Laboratories, Abbvie, Abcam, Abcodia, Abramson Cancer Center, Academic Medical Center, Accelerate Diagnostics, AccuGenomics, Accu Reference Medical Laboratory, AC Immune, Acumen Pharmaceuticals, Adaptive Biotechnologies, Adaptive Phage Therapeutics, Adarza BioSystems, ADC Therapeutics, Admera Health, Aduro BioTech, Advanced Cell Diagnostics, Advanced Nuclear Medicine Ingredients, Advaxis, Aelan Cell Technologies, Aerocrine, Affigen, AFFiRiS, Affymetrix, Age Labs, Agendia, Agilent Technologies, Agios Pharmaceuticals, Air Force Research Laboratory, AIT Laboratories, Akers Biosciences, AKESOgen, Akili Interactive Labs, Akoya Biosciences, Albert Einstein College of Medicine, Alcyone Lifesciences, Alector, Alexion Pharmaceuticals, Alion Pharmaceuticals, Allele Biotechnology and Pharmaceuticals, AlloSource, Allscripts, Almac Diagnostics, Alpha Genomix Laboratories, ALS Association, ALS Finding a Cure Foundation, Altor BioScience, Alzeca Biosciences, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimers Research UK, Amarantus BioSciences, Amarna Therapeutics, Ambiopharm, American Association for Cancer Research, American Association of Neuromuscular & Electrodiagnostic Medicine, American Diabetes Association, AmerisourceBergen, Amgen, AmorChem, Amoy Diagnostics, AmpTec, AMRA, Analytics Engines, Anam Hospital, Anavex Life Sciences, Angle, Anivive Lifesciences, Annoroad, Apocell, Apogenix, Appistry, Applied DNA Sciences, Arbor Biosciences, Arbor Biotechnologies, ArcherDX, ARCH Personalized Medicine Initiative, Arcis Biotechnology, Arcus Biosciences, Arcus Therapeutics, Arno Therapeutics (inactive since 2017), AroCell, Array Biopharma, Arrow Diagnostics, Artialis, Ascenion, Assistance Publique-Hôpitaux de Paris, Association for Frontotemporal Degeneration, Assurex Health, Assuta Medical Centers, Astellas Pharma, Asterand Bioscience, Asthma UK, AstraZeneca, Astute Medical, Asuragen, Aural Analytics, Auria Biobank, Aurigene Discovery Technologies, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), Austrian Institute of Technology, Autifony Therapeutics, AutoGenomics, AVEO Oncology, Avera Health, Avera Heart Hospital of South Dakota, Aviana Molecular Technologies, Avidity Biosciences, Ayasdi, AyoxxA Biosystems, Bank of America, Banyan Biomarkers, Basepaws, Baxter International, Bayer, Bayer Healthcare, Baylor College of Medicine, BC Platforms, BeiGene, Beijing Genomics Institute (BGI), Beijing InnoCare Pharma, Berg, Bertin Pharma, Beth Israel Deaconess Medical Center, BGI, BGI Tech Solutions, Bill and Melinda Gates Foundation, Bio-Techne, BioArctic Neuroscience, Biocartis, Biocept, Biodesix, BioDiscovery, Biofidelity, Biogen, Biognosys, Biohealth Innovation, BioLum Sciences, BioMarker Strategies, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), bioMerieux, BiomX, BioNTech, BioPorto, Biopsy Sciences, BioReference Laboratories, BioRestorative Therapies, Biosearch Technologies, Biotest, Biothera, BioTheranostics, BioVendor, Bioyong, Bird Foundation, Blackfynn, BlackThorn Therapeutics, Blinktbi, Bliss Biopharmaceutical, Blue Cross Blue Shield Association, BluePen Biomarkers, Blueprint Medicines, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Boston University School of Medicine, Bpifrance, Brain Biomarker Solutions in Gothenburg, BrainScope, Breath Diagnostics, Brigham and Women's Hospital, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Broad Institute, Brooks Automation, Brown University, Buck Institute for Age Research, BurstIQ, C2N Diagnostics, Cachet Pharma, Caladrius Biosciences, California Institute for Biomedical Research, California Institute for Regenerative Medicine, California Stem Cell, Cambia Health Solutions, Cambridge Epigenetix, Cambridge Isotope Laboratories, Canadian Cancer Society, Canadian Cancer Trials Group, Canadian Institutes of Health Research, Canadian National Transplant Research Program, CANbridge Life Sciences, Cancer Genetics, Cancer Immunotherapy Trials Network, Cancer Research Institute, Cancer Research Society, Cancer Research UK, Canopy Biosciences, Cantonal Hospital, Caprion Biosciences, Caprion Proteomics, Caraway Therapeutics, CARB-X, Caris Life Sciences, Carlos Slim Health Institute, Carmentix, Carolina BioOncology Institute, Carolinas Medical Center (CMC), CarThera, Case Western Reserve University, CASI Pharmaceuticals, Catalan Institute of Nanotechnology (ICN), Catalyn Medical Technologies, Catholic University Leuven, CBD Solutions, CBLPath, CDx Diagnostics, Cedars-Sinai Medical Center, Celgene, Cellgen Diagnostics, Cellnetix, Cell Signaling Technology, Celmatix, Celsee, Celsius Therapeutics, Cenix BioScience, Centene, Center for Biomarker Research in Medicine, Center for Human Immunology, Autoimmunity and Inflammation, Centers for Disease Control and Prevention, Centogene, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Centre for Imaging Technology Commercialization, Centre For Proteomic & Genomic Research, Centre Hospital University - Bordeaux, Centre Leon Berard, Centre National de la Recherche Scientifique, CerebraCell, Certainty Health, Certis, Cerveau Technologies, Chan Soon-Shiong Institute of Molecular Medicine, CHDI Foundation, Chek Diagnostics, Chembio Diagnostics, Children's Hospital Boston, Children's Hospital of Orange County, Children's Medical Research Institute, Children's Minnesota, Children's Research Institute, Children’s Center for Cancer and Blood Diseases (CCCBD), Children’s Hospital Colorado, Children’s Hospital Oakland Research Institute (CHORI), Christian Doppler Research Association, Chugai Pharmaceutical, Cicero Diagnostics, Cincinnati Children’s Hospital Medical Center, Circulogene, Citizens United for Research in Epilepsy, City of Hope, Clarient, Clearbridge Biomedics, Cleveland Clinic, Cleveland HeartLab, Clevexel Pharma, Clinical Genomics, Clinical Outcomes Tracking and Analysis, Clinica Ruiz, Cloudera, Cloud Pharmaceuticals, Clovis Oncology, Cognition Therapeutics, Cohen Veterans Bioscience, Color, Columbia University, Columbia University Medical Center, Combating Terrorism Technical Support Office, CompanionDx Reference Lab, Companion Dx Reference Lab, Companion Medical, Compugen, Concerto HealthAI, Contextual Genomics, COPD Foundation, CoreBiome, Core Diagnostics India, Corgenix Medical, Coriell Life Sciences, Cornell University, Corning, Cosmo Bio, COTA, Courtagen Life Sciences, Covance, CRC Health, Critical Diagnostics, Crohn's and Colitis Foundation of America, Crossbeta Biosciences, Crown Bioscience, CSIRO, CStone Pharmaceuticals, Cure Forward, CURE Pharmaceutical, Curetis, Curie-Cancer, Curis, CvergenX, Cyclica, Cypher Genomics, CytoLumina Technologies, CYTOVIA Therapeutics, Cytox, Daiichi Sankyo, Dako, DalCor Pharmaceuticals, Dana-Farber Cancer Institute, Danish Center for Strategic Research into Type 2 Diabetes, DarioHealth, DarwinHealth, Datavant, David H. Koch Institute for Integrative Cancer Research, Debiopharm, Defense Advanced Research Projects Agency, Definiens, Dell, Deloitte, Denovo Biopharma, Department of Defense, Department of Veterans Affairs, DestiNA Genomics, Devicor Medical Products, DiaCarta, Diaceutics, diaDexus, DiagnoCure, DiamiR, DIAN Diagnostics, Diaxonhit, Dimerix Biosciences, Diversigen, DNAnexus, DNA Software, DNA Therapeutics, Dow AgroSciences, DrChrono, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University Medical Center, DZNE German Center for Neurodegenerative Diseases, e-NIOS, Early Signal Foundation, Eccrine Systems, ECOG-ACRIN Cancer Research Group, Edico Genome, Edith Cowan University (ECU), Eisai, Eisai Inc, EKF Diagnostics, Eleven Biotherapeutics, Eli Lilly, EMD Millipore, EMD Serono, Emmaus Medical, Emory University, Empire Genomics, Emulate, Enable Healthcare, EnBiotix, Enigma Biomedical, Enterome Bioscience, Entia Biosciences, Epicore Biosystems, Epic Sciences, Epigenomics, Epinomics, Epizyme, Erasmus University Medical Center, Etubics, Eureka Eurostars, Eurofarma, Eurofins Genomics, European Commission, European Medical Contract Manufacturing, European Organization for Research and Treatment of Cancer, European Union, Eutropics Pharmaceuticals, Evogen, Evotec, Exactis Innovation, Exact Sciences, Excelra, Exosome Diagnostics, Exosome Sciences, Expesicor, Exploragen, Expression Analysis, Ezose Sciences, F-Star Alpha, Fabric Genomics, Federal Ministry of Education and Research (BMBF), FedMed, Feinstein Institute for Medical Research, Feist-Weiller Cancer Center, Ferring Pharmaceuticals, FetoLumina Technologies, Fibrocell Science, First Databank, Five Prime Therapeutics, Flagship Biosciences, Flatiron Health, Flemish agency for Innovation by Science and Technology, Florida Hospital, FlowMetric Life Sciences, Flow Pharma, Fluidigm, Fluofarma, Fluxion Biosciences, Food and Drug Administration (FDA), FORMA Therapeutics, Fortified Provider Network, Fosun Pharmaceutical, Foundation for Innovative New Diagnostics, Foundation for the National Institutes of Health (FNIH), Foundation Medicine, Fred Hutchinson Cancer Research Center, Freenome, Frontage Laboratories, Fudan University, Fujirebio Diagnostics, Fusion Antibodies, G-TAC, G1 Therapeutics, Gallus Biopharmaceuticals, Galmed Pharmaceuticals, GC Pharma, GE Healthcare, Geisinger Health System, Gemini Therapeutics, Gen-Probe, GeneCentric Therapeutics, GeneDX, Geneformics, Genelex, GeneNews, Genentech, Geneos Therapeutics, General Electric (GE), Genetron Health, Geneva Foundation, Geneva University Hospitals, Genialis, Genmab, GenoLogics, Genomac Research Institute, GenomeDx, Genome Institute of Singapore, Genomeon, Genomics, Genomic Testing Cooperative, Genomind, Genomoncology, GenoSpace, Genovive, Genprex, GenTegra, Gentris, GenVec, GenXys, George Mason University, Georgetown University, Georgetown University Hospital, George Washington University, Gestion Univalor, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, GLG Pharma, Global Discovery Biosciences, Global Genomics Group, Gloval Specimen Solutions, Glycotest, Glykos, Glympse Bio, Glythera, GMSbiotech, Gnome Diagnostics, Gnosis Bioresearch, GNS Healthcare, Goldfinch Bio, Grace Bio-Labs, Grail, GrandOmics Biosciences, Grand Valley State University, Gritstone Oncology, Grunenthal, Guardant Health, Gubra, H3 Biomedicine, Hadasit Bioholdings, HalioDx, Halozyme Therapeutics, Hamad Bin Khalifa University, Hannover Medical School, Haplogen, Harlan Laboratories, HEALTH Biomed, Healthcare Global Enterprises, Health Diagnostics Laboratory, Health Sciences Research Institute Germans Trias i Pujol Foundation, Heartflow, HeartScore, Heat Biologics, Hebrew University of Jerusalem, Helen F Graham Cancer Center, Helix, Helomics, HemaTone, Hennepin County Medical Center, Henry Ford Health System, Henry M. Jackson Foundation, HMNC Brain Health, Hoag Memorial Hospital Presbyterian, Hologic, Hope for Stomach Cancer, Horizon 2020, Horizon Discovery, Horizon Healthcare Services, Hospital del Mar, Hoth Therapeutics, HSRx Group, HTG Molecular Diagnostics, Huawei, Human Longevity, Huntsman Cancer Institute, IBM, IBM Watson Health, Icahn School of Medicine at Mount Sinai, IDbyDNA, Idera Pharmaceuticals, ID Pharma, Ignyta, ILiAD Biotechnologies, Illumina, ImaBiotech, Image Analysis, ImaginAb, Imanis Life Sciences, Imanova, IMIDomics, Immodulon Therapeutics, ImmuDyne, ImmunArray, Immune Design, Immune Pharmaceuticals, Immunexpress, ImmunID Technologies, ImmunoCellular Therapeutics, ImmunoGen, Immunovia, Imperial College London, IMS Health, Imugene, In-Q-Tel, IncellDx, INC Research, Incyte, Independent Medical Coop, Indica Labs, Indivumed, Informed Data Systems, Inform Genomics, Innate Pharma, InnaVirVax, Innovate UK, Innovative Medicines Initiative (IMI), Inotrem, Inova Diagnostics, Inova Genomics Laboratory, Inova Health System, Inova Labs, Inova Translational Medicine Institute, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Insight Genetics, Institut Curie, Institute for Genome Statistics and Bioinformatics, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for Systems Biology, Institute of Cancer Research, Institute of Crop Sciences, Institute of Human Genetics, Institut Gustave Roussy, Instituto Valenciano De Oncologia, Institut Pasteur, IntegraGen, Integra LifeSciences, Integrated Biobank of Luxembourg, Intermountain Healthcare, International Progressive MS Alliance, Interpace Diagnostics, Interpace Diagnostics Group, InterpretOmics, InterSystems, Intezyne, Intrinsic LifeSciences, Invectys, Invenshure, inVentiv Health, Invetech, inviCRO, InVivoScribe, IO Biotech, ION Solutions, Ion Torrent, IPMD, Irish Haemophilia Society, IROA Technologies, Ironwood Pharmaceuticals, IRX Therapeutics, Isotope Technologies Garching, iSpecimen, iThera Medical, Jackson Laboratory, Jaguar Health, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jazz Pharmaceuticals, Jewel-Osco, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, John Wayne Cancer Institute, Joshua and Marjorie Harris, Jounce Therapeutics, JPT Peptide Technologies, Juventas Therapeutics, Kailos Genetics, Kairos Therapeutics, Kalgene Pharmaceuticals, Keck Graduate Institute of Applied Life Sciences, Keck School of Medicine of USC, KineMed, Kinetic Dx, KingMed Diagnostics, Kings College London, Kiyatec, Kleiner Perkins Caufield & Byers, Knight Cancer Institute, Knight Diagnostic Laboratories, Konica Minolta, KPMG, Kymab, Laboratory Corporation of America, La Jolla Institute for Allergy & Immunology, Lantern Pharma, Lantheus Holding, Lee Moffitt Cancer Center, Leica Biosystems, Leidos Holdings, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LGS Foundation, Lifecode, LifeLabs Medical Laboratory Services, LifeOmic, Li Ka Shing Foundation, LineaRx, Lipotype, Liquid Biotech USA, Livongo Health, Lockheed Martin, Locus Biosciences, Louisiana State University, Loxo Oncology, Lucid Diagnostics, Lumiphore, Lundbeck, Lunenfeld-Tanenbaum Research Institute, Lung Cancer Alliance, Lupus Foundation of America (LFA), Luye Pharma Group, Lysosomal Therapeutics, M3, Maccura Biotechnology, Macrogen, Maisonneuve-Rosemont Hospital (HMR), Mannin Research, Maryland Stem Cell Research Fund, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Maxim Integrated, Maxim Ventures, Mayo Clinic, MBio Diagnostics, MC10, McGill University, McKesson, McMaster University, MD Anderson Cancer Center, MD Biosciences, MDxHealth, med fusion, MedGenome, MEDIAN Technologies, Medical Prognosis Institute, Medical Research Council, Medical University of Bialystok, Medical University of Graz, Medical University of Innsbruck, Medical University of South Carolina, Medicinal Genomics, Medicines Discovery Catapult, MediciNova, Medidata Solutions, MedImmune, MediSapiens, Medivation, Medley Genomics, Medosome Biotec, Medtronic, Melanoma Research Foundation, Memorial Sloan Kettering Cancer Center, Mendel Health, Merck and Co, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Merrimack Pharmaceuticals, Metabolon, Metanomics Health, Metro Orthopedics and Sports Therapy, Michael J Fox Foundation, Michelson Diagnostic, Microbiotica, Microsoft, Mikrogen, Millennium Medical Devices, MiNDERA, Mindstrong Health, Minerva Biotechnologies, Miraculins, Mirati Therapeutics, MirImmune, Mirnax Biosens, MiRXES, Mitra Biotech, Mitsubishi Tanabe Pharma, Moderna Therapeutics, MolecularMD, Mologen, Monsanto, Montreal Heart Institute, Moores Cancer Center, Morphotek, Mount Sinai Medical Center, Mount Sinai Services, Movember Foundation, MRM Proteomics, MultiPlan, Multiple Myeloma Research Foundation, Mundipharma, Munich Leukemia Laboratory, Munich Technical University, Muscular Dystrophy Association, Muses Labs, MyCartis, MyHealios, Myriad Genetics, Myriad RBM, N-of-One, Nancy and Stephen Grand Israel National Center for Personalized Medicine, Nancy Lurie Marks Family Foundation, NanoMab Technology, NanoString Technologies, NanoView Biosciences, NantCell, NantHealth, NantKwest, NantWorks, NASA, National Cancer Center, National Cancer Center of South Korea, National Cancer Centre Singapore, National Cancer Institute, National Center for Tumor Diseases, National Geographic, National Healthcare Services (NHS), National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health, National Institute of Molecular Genetics, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Science Foundation, Navican, Navy Medical Research Centre, NEC, Nektar Therapeutics, Nemucore Medical Innovations, Neogenomics, NEO New Oncology, Neon Therapeutics, Neoteryx, NerPharMa, Nerviano Medical Sciences, Nestle, Netherlands Cancer Institute, NetScientific, Neuraltus Pharmaceuticals, NeurExo Sciences, NeuroLex Laboratories, NeuroPointDX, NeuroTrauma, New Brunswick Health Research Foundation, Newcastle University, Newomics, New York Genome Center (NYGC), New York Medical College, Nightingale Health, NMI TT Pharmaservices, Nodality, Nordic Bioscience, North Carolina State University, Northeast ALS Consortium, Northwell Health, Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, Novartis, Nova Southeastern University, Novation, NovellusDx, Novogene, Nrgene, Nuclea Biotechnologies, Nucleai, Nucleix, NuGen Technologies, NuMedii, NuSirt, NuView Life Sciences, NxGEN MDx, NX Prenatal, Oklahoma Medical Research Foundation, Olaris, Oligomerix, Olink Bioscience, Olympus Respiratory America, OmicScouts, Oncgnostics, Oncimmune, Oncimmune Ltd, Oncoceutics, OncoCyte, Oncodesign, OncoDNA, OncoGenesis, OncoHost, OncoImmunity, Oncologie, Oncology Venture, OncoMed Pharmaceuticals, Oncora Medical, OncoSec Medical, Oneome, One Way Liver Genomics (OWL), Ono Pharmaceutical, Ontario Cancer Biomarker Network, Ontario Institute for Cancer Research, Open Medicine Institute, OPKO Health, Optina Diagnostics, Oregon Health Sciences University, Ortho-Clinical Diagnostics, OSE Immunotherapeutics, OSEO, Oslo University Hospital, Otsuka, Oventus, Ovid Therapeutics, Owlstone Medical, Oxford Biodynamics, Pacific Biomarkers, Pacific Biosciences, Pacific Northwest Research Institute, Pais Vasco University, Palantir, Panaceutics, Pan American Cancer Treatment Centers, Pancreatic Cancer Action Network, PANTHERx Specialty Pharmacy, Paradigm, Parent Project Muscular Dystrophy, Parexel, Paris Descartes University, Parkinson's Institute and Clinical Center, Partners HealthCare, PathAI, Pathway Genomics, Patia, PAVmed, PEAR Therapeutics, Pelago Bioscience, Pennsylvania State University, Pepscan Therapeutics, PerkinElmer, Personal Genome Diagnostics, Personalis, Personalized Medicine Initiative (PMI), PersonalizeDx, Perthera, PETNET Solutions, Pfizer, Phadia, Pharmaco-Kinesis, Pharmatech, PierianDx, Pierre Fabre, Pittsburgh Life Sciences Greenhouse, Plasticell, Poietis, PointCross Life Sciences, PPD, Precision Biologics, Precision for Medicine, Precision NanoSystems, Precision Therapeutics, PredictImmune, Premas Life Sciences, Premier Inc, Prescient Medical, Prestizia, Prevacus, PRIMA BioMed, Princess Margaret Hospital, Prism Research, Probiodrug, Procter & Gamble, Profil Institute for Clinical Research, Profusa, Progenics Pharmaceuticals, Progknowse, Prognos, Prometheus Laboratories, ProMIS Neurosciences, ProNova, Propagenix, Prosenex, Prostate Cancer Foundation (PCF), Protagen, Protagonist Therapeutics, Protea Biosciences, Protean BioDiagnostics, Proteomics International, Pryzm Health, Psyche Systems, Pulmonary Fibrosis Foundation (PFF), Puma Biotechnology, Pure MHC, Pure Protein, Q-State Biosciences, Q2 Solutions, Q BioMed, QED Therapeutics, Qiagen, Quadrant Biosciences, Quanterix, Quantum Design International, QuantumDx, Quantum Leap Health Care Collaborative, Quest Diagnostics, Quintiles, R-Biopharm, Rady Children's Institute for Genomic Medicine, Rare Disease Specialty Pharmacy, RayBiotech, RCK, Readout Health, Redx Pharma, Regen BioPharma, RegenWell, Regulus Therapeutics, Renji Hospital, Renovar, ReproCell, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Research Council of Norway, Research Foundation of State University of New York, Research Institute of the Hospital Universitari Vall d'Hebron, Resolution Bioscience, Response Genetics, Rett Syndrome Research Trust, Reveal Biosciences, rEVO Biologics, Revolution Medicines, Rhythm Pharmaceuticals, RiboMed, Ridge Diagnostics, Robert H. Lurie Comprehensive Cancer Center, Roche, Roche Diagnostics, Rosetta Genomics, Royal College of Surgeons (Ireland), Royal Philips Electronics, RPRD Diagnostics, RTI International, Rush University Medical Center, Rx30, RxGenomix, RXi Pharmaceuticals, Rx Review Service, Saladax Biomedical, Sanford Burnham Institute, Sanguine, Sanofi, Sanofi-Pasteur, San Raffaele Hospital, Saphetor, Sarah Cannon Research Institute, Sarepta Therapeutics, Sayre Therapeutics, Scancell, Science Foundation Ireland, Scienion, Sciex, Sciton, Scripps Research Institute, Seahorse Bioscience, Seattle Genetics, Second Genome, Sedona Integrative Medical Clinic, Seed Mena, Seizure Tracker, SeLux Diagnostics, Semma Therapeutics, Sengenics, Sentieon, Sentinel Oncology, Seoul National University, Seoul National University Bundang Hospital, Seracare Life Sciences, Seven Bridges Genomics, Shanghai Biotechnology, Shanghai Institutes of Preventative Medicine, Sheba Medical Center, Shenzhen Chipscreen Biosciences, Shire Human Genetic Therapies, Shuwen Biotech, Siemens, Siemens Healthineers, Sigma-Aldrich, Silicon Biosystems, Siloam Biosciences, Singapore Eye Research Institute (SERI), Singlera Genomics, Singulex, SkylineDX, Skyline Medical, Small Business Innovation Research, SolaranRx, SOLTI, SomaGenics, SomaLogic, Sonic Healthcare, Sony DADC, Sophia Genetics, Soricimed Biopharma, Sorrento Therapeutics, Spectral Medical, Spectrum Pharmaceuticals, Sphingotec, Splicos, SQI Diagnostics, SRI International, SRL, St. Jude Children's Research Hospital, Stand Up To Cancer, Stanford University, Stanford University School of Medicine, STC.UNM, Stemina Biomarker Discovery, St Jude Crosson Cancer Institute, Strain Genie, Strand Life Sciences, Strata Oncology, STRATIFYER Molecular Pathology, Stratose, Stroke Detection Plus, Summit Therapeutics, Sunnybrook Health Sciences Centre, Sunquest Information Systems, SUNY Upstate Medical University, Supernus Pharmaceuticals, Surefire Medical, Surrey Cancer Research Institute, Sutro Biopharma, Syapse, Sydys Corporation, Symbiodx, Synlogic, Synthetic Biologics, Syros Pharmaceuticals, Sysmex, Sysmex Inostics, TaiRx, TaiRx US, Takeda Pharmaceutical, Tampere University Hospital, Tandem Diabetes Care, TapGenes, Targos, Tasly Pharmaceuticals, Tasso, TATAA Biocenter, Technology Foundation STW, Technology Transfer Accelerator, Telix Pharmaceuticals, Telo Therapeutics, Tempus, Terry Fox Foundation, Tesaro, Tetra Discovery Partners, Teva Pharmaceutical Industries, The Cyprus Institute of Neurology and Genetics, The Fleury Group, The National Football League, The New York Stem Cell Foundation, The Parker Institute For Cancer Immunotherapy, Theradiag, Theranostics Health, Therapix Bio, Thermo Fisher Scientific, The Technical University Of Munich, The University of Chicago Medicine, Thomas Jefferson University, Thomson Reuters, Thorne Research, Three Rivers Provider Network, Three S Japan, Threshold Pharmaceuticals, Tiziana Life Sciences, TMRC, TNK Therapeutics, Tocagen, Tokai Pharmaceuticals, Tolero Pharmaceuticals, Toronto Innovation Acceleration Partners, Tor Vergata University Hospital, Toshiba Medical Systems Corporation, Toulouse University Hospital, TP Therapeutics, Traaser, TRACON Pharmaceuticals, Trakcel, Transgene, Transgenomic, Translational Drug Development, Translational Genomics Research Institute, Translational Medicine Accelerator, Translational Software, Transmed Systems, Transplant Genomics, TrovaGene, TTFactor, TumorGenesis, Turnstone Biologics, Tymora Analytical Operations, TypeZero Technologies, uBiome, UCB, UCF College of Medicine, UK Government, Ultivue, UNICANCER, Unilab, Unilabs, Unilife, United Therapeutics, University Ann & Robert H. Lurie Children’s Hospital, University College London, University of Adelaide, University of Alabama at Birmingham, University of Arizona, University of Bonn, University of Bristol, University of British Columbia, University of California, University of California, Davis, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cincinnati, University of Colorado Denver, University of Florida, University of Greifswald, University of Lausanne, University of Leeds, University of Manchester, University of Massachusetts, University of Massachusetts Medical School, University of Melbourne, University of Michigan, University of Minnesota, University of Montreal, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Rochester, University of Rostock, University of Southampton, University of South Carolina, University of Surrey, University of Texas, University of Texas Southwestern Medical Center, University of Tokyo, University of Toronto, University of Turin, University of Virginia, University of Washington, University Pierre Marie Curie, US Bioservices, USC Norris Comprehensive Cancer Center, US Department of Commerce, US Oncology, Vancouver Prostate Centre, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Varian Medical Systems, VCC Medical, Vector Oncology, Vela Diagnostics, Ventana Medical Systems, Veracyte, Veravas, VerdePharmHealth, Verily, Veritas Genetics, Vertex Pharmaceuticals, VGXI, Vida Diagnostics, VieCure, ViewRay, Vigilant Biosciences, Vineti, Viome, Virax, Vir Biotechnology, Virginia Commonwealth University, Virginia Polytechnic Institute and State University, Visterra, Vitatex, Vivante Health, ViveBio, Vividion Therapeutics, Viviphi, Vivo Biosciences, VolitionRX, Voluntis, VU Medical Center, Vyriad, Vyripharm, Walgreens, Walter Reed Army Institute of Research, WardMM, Washington University in St Louis, Waters Corporation, WAVE Life Sciences, Wearifi, Weill Cornell Medical College, Weizmann Institute, Wellcome Trust Sanger Institute, West China Hospital, Weston Brain Institute, Windber Research Institute, WinterLight Labs, Worldwide Innovative Network (WIN) in personalized cancer medicine Consortium, Wuxi Apptec Laboratory Services, WuXi NextCODE Genomics, WuXi PharmaTech, Wyss Institute, Xcell Biosciences, Xenon Pharmaceuticals, Yale School of Medicine, Yale University, Yissum Research Development, Ymir Genomics, Zellkraftwerk, Zionexa, Zymeworks

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.